Dapagliflozin and metabolic dysfunction-associated steatohepatitis: Improves fibrosis and steatohepatitis

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), progressive fibrosis, cirrhosis, and hepatocellular carcinoma. MASLD is currently the leading cause of chronic liver disease, and one of the leading causes of cirrhosis and liver cancer, with an estimated prevalence of 30% worldwide.6 Prevalence has increased substantially in recent decades, primarily driven by the worldwide rise of obesity and type 2 diabetes mellitus...